Ignite Creation Date:
2024-05-05 @ 6:37 PM
Last Modification Date:
2024-10-26 @ 9:35 AM
Study NCT ID:
NCT00513279
Status:
COMPLETED
Last Update Posted:
2017-09-15
First Post:
2007-08-06
Brief Title:
To Investigate If Single Doses Of GSK618334 Are Safe And To Investigate Blood Levels Of GSK618334
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A First Time in Human Blinded Randomised Placebo-Controlled Two-cohort Study to Investigate the Safety Tolerability and Pharmacokinetics of Single Oral Escalating Doses of GSK618334 in Healthy Male Volunteers
Status:
COMPLETED
Status Verified Date:
2017-09
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
GSK618334 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders This study will evaluate the safety tolerability and pharmacokinetics of single doses of GSK618334 in healthy volunteers
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None